Diversified Revenue Merakris recently launched AmnioSurge and formed a strategic partnership with 360 Medical, creating a new surgical revenue channel that sales teams can target by offering regenerative amniotic membrane products to hospitals and surgical centers.

Public Funding Momentum With SBIR direct-to-Phase II funding of approximately 2.2 million and ongoing IND development for MTX-001, there is a strong opportunity to align market access, partnerships, and payer strategies around regenerative biotherapeutics and wound care solutions.

Government channels Recent federal market actions include a U.S. Department of Veterans Affairs Federal Supply Schedule contract, indicating potential near-term and ongoing opportunities to supply Dermacyte AC Matrix Amniotic Membrane Allograft and related products to federal healthcare facilities.

Clinical Development Active IND discussions for MTX-001 targeting venous leg ulcers suggest a pathway to secured clinical data and later-stage adoption, offering co-development or licensing opportunities with larger biotechs or contract research organizations.

Regenerative Focus Strong emphasis on stem cell–derived regenerative therapies positions Merakris as a partner for wound healing, tissue regeneration, and reduced-treatment paradigms, enabling cross-sell to hospitals, wound care centers, and long-term care providers seeking cost-effective care improvements.